Czopek Anna, Jończyk Jakub, Fryc Monika, Kluzik Daria, Zagórska Agnieszka
Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
ACS Chem Neurosci. 2025 Jun 18;16(12):2163-2177. doi: 10.1021/acschemneuro.5c00152. Epub 2025 Jun 6.
Millions worldwide suffer from chronic pain, a complex condition often accompanied by depression and anxiety, highlighting the urgent need for innovative treatments. Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), and ,-dimethyltryptamine (DMT), primarily act on serotonin 5-HT receptors and have emerged as potential modulators of pain perception and mood regulation. These substances may offer an alternative to conventional analgesics, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), by influencing neuroplasticity, descending pain modulation pathways, and inflammatory processes. Evidence from case studies, preclinical research, and early phase clinical trials suggests that psychedelics may alleviate pain in conditions such as cluster headaches, migraines, fibromyalgia, and chronic pain syndromes. However, the exact mechanisms underlying their analgesic properties are yet to be fully understood. While psychedelics show promise in reshaping pain management strategies, rigorous randomized controlled trials are needed to establish their safety, efficacy, and optimal dosing. This review highlights the therapeutic potential of psychedelics for chronic pain and emphasizes the necessity of further research to validate their role in modern pain medicine.
全球数百万人饱受慢性疼痛之苦，这是一种复杂的病症，常伴有抑郁和焦虑，凸显了对创新治疗方法的迫切需求。经典迷幻剂，包括裸盖菇素、麦角酸二乙酰胺（LSD）和N，N-二甲基色胺（DMT），主要作用于血清素5-羟色胺受体，并已成为疼痛感知和情绪调节的潜在调节剂。这些物质可能通过影响神经可塑性、下行性疼痛调节通路和炎症过程，为阿片类药物和非甾体抗炎药（NSAIDs）等传统镇痛药提供一种替代方案。病例研究、临床前研究和早期临床试验的证据表明，迷幻剂可能缓解丛集性头痛、偏头痛、纤维肌痛和慢性疼痛综合征等病症中的疼痛。然而，其镇痛特性的确切机制尚未完全明了。虽然迷幻剂在重塑疼痛管理策略方面显示出前景，但需要严格的随机对照试验来确定其安全性、有效性和最佳剂量。本综述强调了迷幻剂对慢性疼痛的治疗潜力，并强调了进一步研究以验证其在现代疼痛医学中作用的必要性。
